Stock ALGEN GENOWAY
Add to a list
To use this feature you must be a member
Log inSign up

Financials genOway

Equities

ALGEN

FR0004053510

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 07:16:14 26/04/2024 pm IST 		5-day change 1st Jan Change
3.97 EUR +0.25% Intraday chart for genOway +1.02% -13.70%
2023 GenOway: sharp rise, broker initiates buy recommendation CF
2023 GENOWAY : Euroland initiates buy coverage CF

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 11.91 12.6 7.32 21.45 37.85 35.3
Enterprise Value (EV) 1 11.71 14.21 12.25 29.49 43.07 39.45
P/E ratio 6.16 x 22.1 x - - - -
Yield - - - - - -
Capitalization / Revenue 0.94 x 0.84 x 0.52 x 1.32 x 1.93 x 1.67 x
EV / Revenue 0.92 x 0.95 x 0.88 x 1.81 x 2.2 x 1.87 x
EV / EBITDA 11.2 x 9.96 x 22.9 x 34.9 x 99.8 x 13.1 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 1.65 x 1.6 x - - - -
Nbr of stocks (in thousands) 5,955 5,832 5,856 6,919 8,824 8,824
Reference price 2 2.000 2.160 1.250 3.100 4.290 4.000
Announcement Date 25/05/18 30/04/19 04/05/20 28/04/22 28/04/22 28/04/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 12.73 14.95 13.99 16.29 19.59 21.09
EBITDA 1 1.049 1.427 0.5342 0.844 0.4318 3.006
EBIT 1 0.7108 0.5798 -0.6461 -0.3771 -0.7893 0.4886
Operating Margin 5.58% 3.88% -4.62% -2.32% -4.03% 2.32%
Earnings before Tax (EBT) 1 1.931 0.5492 -0.9732 -0.6108 -0.3519 0.7589
Net income 1 1.931 0.5716 -1.036 -0.6873 -0.3226 0.7778
Net margin 15.17% 3.82% -7.41% -4.22% -1.65% 3.69%
EPS 2 0.3249 0.0978 - - - -
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 25/05/18 30/04/19 04/05/20 28/04/22 28/04/22 28/04/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - 1.62 4.93 8.05 5.22 4.16
Net Cash position 1 0.2 - - - - -
Leverage (Debt/EBITDA) - 1.133 x 9.228 x 9.532 x 12.09 x 1.383 x
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) 31% 7.58% -14.1% -8.68% -2.72% 5.04%
ROA (Net income/ Total Assets) 3.08% 1.97% -2.08% -1.01% -1.64% 0.93%
Assets 1 62.75 29.07 49.84 68.13 19.69 83.51
Book Value Per Share 2 1.210 1.350 - - - -
Cash Flow per Share 2 0.6600 0.5200 - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 25/05/18 30/04/19 04/05/20 28/04/22 28/04/22 28/04/23
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENOWAY Stock genOway
-13.70% 38.19M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALGEN Stock
  4. Financials genOway